NASDAQ:ANAB AnaptysBio Q3 2024 Earnings Report $23.40 +0.20 (+0.86%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.40 0.00 (0.00%) As of 09/12/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast AnaptysBio EPS ResultsActual EPS-$1.14Consensus EPS -$1.72Beat/MissBeat by +$0.58One Year Ago EPSN/AAnaptysBio Revenue ResultsActual Revenue$30.02 millionExpected Revenue$7.92 millionBeat/MissBeat by +$22.10 millionYoY Revenue GrowthN/AAnaptysBio Announcement DetailsQuarterQ3 2024Date11/5/2024TimeAfter Market ClosesConference Call DateTuesday, November 5, 2024Conference Call Time3:00PM ETUpcoming EarningsAnaptysBio's Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled at 3:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AnaptysBio Earnings HeadlinesAnaptys Announces Participation in September Investor ConferencesAugust 27, 2025 | globenewswire.comAnaptysBio price target raised to $20 from $18 at UBSAugust 13, 2025 | msn.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)AnaptysBio (ANAB) Receives a Buy from Piper SandlerAugust 8, 2025 | theglobeandmail.com6ANAB : Analyst Expectations For AnaptysBio's FutureAugust 8, 2025 | benzinga.comAnaptysBio (ANAB) Q2 Revenue Jumps 103%August 6, 2025 | fool.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions. The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform. AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine. Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are Done Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
